Cytokinetics Inc (NASDAQ: CYTK) is -27.78% lower on its value in year-to-date trading and has touched a low of $32.74 and a high of $68.44 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $36.67 in the last trading session, with the day’s loss setting it -2.7%.
Currently trading at $33.97, the stock is -12.47% and -18.09% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.92 million and changing -7.36% at the moment leaves the stock -31.31% off its SMA200. CYTK registered -47.20% loss for a year compared to 6-month loss of -33.39%.
The stock witnessed a -9.07% gain in the last 1 month and extending the period to 3 months gives it a -30.96%, and is -17.73% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.31% over the week and 6.69% over the month.
Cytokinetics Inc (CYTK) has around 498 employees, a market worth around $4.05B and $18.47M in sales. Profit margin for the company is -3191.11%. Distance from 52-week low is 3.76% and -50.37% from its 52-week high. The company has generated returns on investments over the last 12 months (-94.66%).
The EPS is expected to shrink by -9.13% this year.
Cytokinetics Inc (CYTK) Top Institutional Holders
The shares outstanding are 118.21M, and float is at 116.05M with Short Float at 12.02%.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 13.4317% of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 10.5485 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 10.4702% and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham, the company’s EVP Research & Development. SEC filings show that Malik Fady Ibraham sold 2,000 shares of the company’s common stock on May 06 ’25 at a price of $35.01 per share for a total of $70020.0. Following the sale, the insider now owns 0.14 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on May 05 ’25 that Callos Andrew (EVP, Chief Commercial Officer) sold a total of 4,002 shares of the company’s common stock. The trade occurred on May 05 ’25 and was made at $36.68 per share for $0.15 million. Following the transaction, the insider now directly holds 60687.0 shares of the CYTK stock.
Still, SEC filings show that on Apr 29 ’25, Blum Robert I (President & CEO) disposed off 5,000 shares at an average price of $40.96 for $0.2 million. The insider now directly holds 417,629 shares of Cytokinetics Inc (CYTK).
